{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:39:27Z","timestamp":1787582367389,"version":"build-2736575974"},"reference-count":56,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diagnosing cystic fibrosis (CF) in adulthood is not a rare occurrence for CF centers despite the popular belief that the diagnosis is achieved almost universally in childhood by means of newborn screening or early clinical presentation. The purpose of this review article is to highlight specific considerations of adult diagnosis of CF. Obtaining a diagnosis of CF at any age is exceptionally important to ensure optimal treatment, monitoring, and support. In the new era of more personalized treatment with the advent of transformative therapies targeting the underlying protein defect, accurate diagnosis is of increasing importance. This review highlights the diagnostic algorithm leading to a new diagnosis of CF in adults. The diagnosis is usually confirmed in the presence of a compatible clinical presentation, evidence of cystic fibrosis transmembrane conductance regulator (CFTR) protein dysfunction, and\/or identification of variants in the CFTR gene believed to alter protein function. Achieving the diagnosis, however, is not always straightforward as CFTR protein function exists on a continuum with different organs displaying varying sensitivity to diminution in function. We highlight the current knowledge regarding the epidemiology of CF diagnosed in adults and outline the various clinical presentations, including pulmonary and extrapulmonary, which are more common in this population. We expand on the stepwise testing procedures that lead to diagnosis, paying particular attention to additional levels of testing which may be required to achieve an accurate diagnosis. There continues to be an important need for both pulmonary and other specialists to be aware of the potential for later presentation of CF, as the improvements in treatment over decades have had large positive impacts on prognosis for people with this condition.<\/jats:p>","DOI":"10.1055\/s-0042-1759881","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:29:57Z","timestamp":1673310597000},"page":"242-251","source":"Crossref","is-referenced-by-count":17,"title":["Diagnosing Cystic Fibrosis in Adults"],"prefix":"10.1055","volume":"44","author":[{"given":"Peter J.","family":"Barry","sequence":"additional","affiliation":[{"name":"Manchester Adult Cystic Fibrosis Centre, Manchester University National Health Service Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Simmonds","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom"},{"name":"National Heart and Lung Institute, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"56","author":"D H Andersen","year":"1938","journal-title":"Am J Dis Child"},{"issue":"S 01","key":"ref2","first-page":"160","article-title":"Cystic fibrosis of the pancreas","author":"P E Di Sant'Agnese","year":"1948","journal-title":"Prog Pediat Study"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1542\/peds.23.3.545","article-title":"A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis","volume":"23","author":"L E Gibson","year":"1959","journal-title":"Pediatrics"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"J R Riordan","year":"1989","journal-title":"Science"},{"issue":"06","key":"ref5","first-page":"513","article-title":"Manifestations of cystic fibrosis diagnosed in adulthood","volume":"11","author":"J A Nick","year":"2005","journal-title":"Curr Opin Pulm Med"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1164\/rccm.200403-404OC","article-title":"Late diagnosis defines a unique population of long-term survivors of cystic fibrosis","volume":"171","author":"D M Rodman","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.rmed.2008.10.011","article-title":"Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis","volume":"103","author":"N J Simmonds","year":"2009","journal-title":"Respir Med"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jcf.2016.12.012","article-title":"The expansion and performance of national newborn screening programmes for cystic fibrosis in Europe","volume":"16","author":"J Barben","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/archdischild-2013-304766","article-title":"Diagnosis of cystic fibrosis in London and South East England before and after the introduction of newborn screening","volume":"99","author":"M TC Lim","year":"2014","journal-title":"Arch Dis Child"},{"issue":"19","key":"ref10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"P G Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"H GM Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/thx.50.12.1301","article-title":"Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years","volume":"50","author":"K H Gan","year":"1995","journal-title":"Thorax"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1378\/chest.118.2.427","article-title":"Health status and sociodemographic characteristics of adults receiving a cystic fibrosis diagnosis after age 18 years","volume":"118","author":"E Widerman","year":"2000","journal-title":"Chest"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/postgradmedj-2020-139278","article-title":"Diagnosis of cystic fibrosis in adulthood and eligibility for novel CFTR modulator therapy","volume":"98","author":"H Farley","year":"2022","journal-title":"Postgrad Med J"},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/diagnostics11020321","article-title":"The Diagnosis of cystic fibrosis in adult age","volume":"11","author":"R Padoan","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCF.2022.09.011","article-title":"ECFS standards of care on CFTR-related disorders: updated diagnostic criteria","author":"C Castellani","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1513\/AnnalsATS.201801-037OC","article-title":"Clinical characteristics and predictors of reduced survival for adult-diagnosed cystic fibrosis","volume":"15","author":"S Desai","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1164\/rccm.201001-0092OC","article-title":"Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis","volume":"182","author":"J A Nick","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"ref20","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1056\/NEJM199306173282403","article-title":"Efficacy of aerosolized tobramycin in patients with cystic fibrosis","volume":"328","author":"B W Ramsey","year":"1993","journal-title":"N Engl J Med"},{"issue":"05","key":"ref21","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"G Z Retsch-Bogart","year":"2009","journal-title":"Chest"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"P A Flume","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"21","key":"ref23","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"S M Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes","volume":"385","author":"P J Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.14309\/ajg.0000000000001527","article-title":"Cystic fibrosis transmembrane conductance regulator modulator use is associated with reduced pancreatitis hospitalizations in patients with cystic fibrosis","volume":"116","author":"M L Ramsey","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis","volume":"21","author":"M J Gould","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jcf.2022.06.005","article-title":"The impact of modulator therapies on pancreatic exocrine function: the good, the bad and the potentially ugly","volume":"21","author":"A J Freeman","year":"2022","journal-title":"J Cyst Fibros"},{"key":"ref28","first-page":"6","article-title":"Is it cystic fibrosis? The challenges of diagnosing cystic fibrosis","volume":"31","author":"N J Simmonds","year":"2019","journal-title":"Paediatr Respir Rev"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jpeds.2016.09.063","article-title":"Applying cystic fibrosis transmembrane conductance regulator genetics and CFTR2 data to facilitate diagnoses","volume":"181S","author":"P R Sosnay","year":"2017","journal-title":"J Pediatr"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"P M Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0140-6736(93)91885-P","article-title":"Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849 + 10\u2009kb C\u2013>T mutation","volume":"342","author":"A Augarten","year":"1993","journal-title":"Lancet"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1569-1993(11)60014-3","article-title":"Recommendations for the classification of diseases as CFTR-related disorders","volume":"10","author":"C Bombieri","year":"2011","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-0004.2009.01294.x","article-title":"Non-classic cystic fibrosis associated with D1152H CFTR mutation","volume":"77","author":"P R Burgel","year":"2010","journal-title":"Clin Genet"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1164\/rccm.201908-1541LE","article-title":"Whole-gene sequencing of CFTR reveals a high prevalence of the intronic variant c.3874-4522A>G in cystic fibrosis","volume":"201","author":"D J Morris-Rosendahl","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-61779-117-8_6","article-title":"Nasal potential difference measurements to assess CFTR ion channel activity","volume":"741","author":"S M Rowe","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"139","key":"ref37","first-page":"57006","article-title":"Standardized measurement of nasal membrane transepithelial potential difference (NPD)","volume":"2018","author":"G M Solomon","year":"2018","journal-title":"J Vis Exp"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1378\/chest.06-2975","article-title":"Reproducibility of nasal potential difference measurements in cystic fibrosis","volume":"132","author":"Y Yaakov","year":"2007","journal-title":"Chest"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1183\/09031936.01.00092501","article-title":"Nasal potential difference measurements in patients with atypical cystic fibrosis","volume":"17","author":"M Wilschanski","year":"2001","journal-title":"Eur Respir J"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/thoraxjnl-2013-203832","article-title":"Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?","volume":"69","author":"C Y Ooi","year":"2014","journal-title":"Thorax"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jcf.2016.06.009","article-title":"Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis","volume":"15","author":"G Tridello","year":"2016","journal-title":"J Cyst Fibros"},{"issue":"04","key":"ref42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jcf.2019.07.001","article-title":"Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism","volume":"19","author":"B L Aalbers","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"08","key":"ref43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thx.2008.104752","article-title":"Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis","volume":"64","author":"C Goubau","year":"2009","journal-title":"Thorax"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thx.2009.125088","article-title":"Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data","volume":"65","author":"N Derichs","year":"2010","journal-title":"Thorax"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2466-14-156","article-title":"Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study","volume":"14","author":"A Bagheri-Hanson","year":"2014","journal-title":"BMC Pulm Med"},{"issue":"05","key":"ref46","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1097\/MPG.0000000000001366","article-title":"Comparison of nasal potential difference and intestinal current measurements as surrogate markers for CFTR Function","volume":"63","author":"M Wilschanski","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"07","key":"ref47","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"J F Dekkers","year":"2013","journal-title":"Nat Med"},{"issue":"08","key":"ref48","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1164\/rccm.201205-0922OC","article-title":"\u03b2-Adrenergic sweat secretion as a diagnostic test for cystic fibrosis","volume":"186","author":"P Quinton","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41231-020-00060-3","article-title":"Rationale and design of the HIT-CF organoid study: stratifying cystic fibrosis patients based on intestinal organoid response to different CFTR-modulators","volume":"5","author":"P van Mourik","year":"2020","journal-title":"Transl Med Commun"},{"issue":"11","key":"ref50","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/thoraxjnl-2020-216368","article-title":"Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis","volume":"76","author":"S Cuyx","year":"2021","journal-title":"Thorax"},{"issue":"05","key":"ref51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bjd.18162","article-title":"CFTR gene variants: a predisposition factor to aquagenic palmoplantar keratoderma","volume":"181","author":"C Raynal","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1164\/ajrccm.162.4.9906120","article-title":"An investigation into causative factors in patients with bronchiectasis","volume":"162","author":"M C Pasteur","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"e233470","DOI":"10.1136\/bcr-2019-233470","article-title":"Microbial clues lead to a diagnosis of cystic fibrosis in late adulthood","volume":"13","author":"C Kerr","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcf.2016.07.012","article-title":"Reduced survival in adult cystic fibrosis despite attenuated lung function decline","volume":"16","author":"C Keating","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"01","key":"ref55","doi-asserted-by":"crossref","first-page":"00056","DOI":"10.1183\/23120541.00056-2016","article-title":"Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His","volume":"3","author":"M Shteinberg","year":"2017","journal-title":"ERJ Open Res"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1183\/09031936.00057309","article-title":"Combination of ENaC and CFTR mutations may predispose to cystic fibrosis-like disease","volume":"34","author":"I Fajac","year":"2009","journal-title":"Eur Respir J"},{"issue":"21","key":"ref57","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis","volume":"368","author":"P D Sly","year":"2013","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2022.09.005","article-title":"ECFS standards of care on CFTR-related disorders: diagnostic criteria of CFTR dysfunction","author":"I Sermet-Gaudelus","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1759881.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T01:24:45Z","timestamp":1678411485000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1759881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":56,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1759881","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}